Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribupatide (KAI-9531) in Obesity or Overweight and Diabetes
NCT07284901Phase 3Active, not recruiting
- Sponsor
- Kailera Therapeutics
- Start
- Jan 2026
- Primary completion
- Mar 2028
- Modality
- Peptides, Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of ribupatide in obesity, type 2 diabetes mellitus (T2DM), sponsored by Kailera Therapeutics. Started Jan 2026; status: active, not recruiting.
02
Drugs
ribupatide
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07284901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07284901.